Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

Tuesday, August 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics' partner, Akeso Inc., reported positive topline results from the Phase III HARMONi-GI1 study. The trial evaluated ivonescimab combined with chemotherapy against durvalumab plus chemotherapy for advanced biliary tract cancer. The results indicate a statistically significant overall survival benefit for the ivonescimab regimen in a single-region study conducted in China.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ivonescimab plus chemotherapy shows significant survival benefit.
  • Study conducted in a multi-center setting enhances reliability.
  • Positive topline results indicate potential for improved treatment options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1236%
120-day peak, hindsight
Typical move
47.7%
average across 2 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
Ivonescimab
Phase 3 · Non-Small Cell Lung Cancer

Full Press Release Details

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusi

Frequently Asked Questions

What is the HARMONi-GI1 study?

The HARMONi-GI1 study is a Phase III trial evaluating ivonescimab plus chemotherapy for advanced biliary tract cancer.

What were the results of the study?

The study showed that ivonescimab plus chemotherapy provided a statistically significant overall survival benefit.

Who conducted the HARMONi-GI1 study?

The study was conducted by Akeso Inc. in China.

What is the comparison treatment in the study?

The study compared ivonescimab plus chemotherapy to durvalumab plus chemotherapy.

ShareAdd on Google
Tags: SMMT Viatris Investor Conferences Healthcare ivonescimab biliary tract cancer Akeso chemotherapy
Last updated: Aug 25, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~14 mo
Low dilution risk
Lead asset
IvonescimabPhase 3
Non-Small Cell Lung Cancer →

Catalyst track record

+1236%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →